Cargando…
Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer
Pancreatic adenocarcinoma remains the fourth leading cause of cancer mortality in the U.S. Despite advances in surgical technique, radiotherapy technologies, and chemotherapeutics, the 5-year survival rate remains approximately 20% for the 15% of patients who are eligible for surgical resection. The...
Autores principales: | Desai, Neelam V, Sliesoraitis, Sarunas, Hughes, Steven J, Trevino, Jose G, Zlotecki, Robert A, Ivey, Alison M, George, Thomas J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559034/ https://www.ncbi.nlm.nih.gov/pubmed/25766842 http://dx.doi.org/10.1002/cam4.444 |
Ejemplares similares
-
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma
por: Singhal, Ruchi, et al.
Publicado: (2023) -
New Primary Malignancy Masquerading as Metastatic Prostate Adenocarcinoma
por: Szwed, Ellen A., et al.
Publicado: (2015) -
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases
por: Gruenberger, Birgit, et al.
Publicado: (2008) -
Neoadjuvant therapy in pancreatic cancer: a systematic review and meta‐analysis of prospective studies
por: Zhan, Han‐Xiang, et al.
Publicado: (2017) -
Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery
por: Cameron, Miles E., et al.
Publicado: (2021)